<code id='928C937896'></code><style id='928C937896'></style>
    • <acronym id='928C937896'></acronym>
      <center id='928C937896'><center id='928C937896'><tfoot id='928C937896'></tfoot></center><abbr id='928C937896'><dir id='928C937896'><tfoot id='928C937896'></tfoot><noframes id='928C937896'>

    • <optgroup id='928C937896'><strike id='928C937896'><sup id='928C937896'></sup></strike><code id='928C937896'></code></optgroup>
        1. <b id='928C937896'><label id='928C937896'><select id='928C937896'><dt id='928C937896'><span id='928C937896'></span></dt></select></label></b><u id='928C937896'></u>
          <i id='928C937896'><strike id='928C937896'><tt id='928C937896'><pre id='928C937896'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion